Market Performance - The Hang Seng Index closed at 25,855 points, up 0.9%, while the Hang Seng China Enterprises Index rose 1.1% to 8,991 points[1] - Total turnover in Hong Kong stocks was HKD 199.8 billion, down 11.0% from HKD 224.5 billion the previous day, indicating a cautious investor sentiment[1] - Energy, materials, and information technology indices increased by 2.4%, 2.3%, and 1.4% respectively, while healthcare, utilities, and consumer staples indices fell by 0.5%, 0.3%, and 0.3%[1] Stock Highlights - Baidu Group (9888 HK) and SMIC (981 HK) led the blue-chip stocks with gains of 8.9% and 4.2% respectively[1] - Pop Mart (9992 HK) and Longfor Group (960 HK) were the biggest losers, down 4.6% and 1.7% respectively[1] - Six new stocks listed in Hong Kong, all closing higher, with notable performances from InnoCare Pharma (3696 HK) and Wuyi Vision (6651 HK), which rose by 24.7% and 29.9% respectively[1] IPO Market Insights - The total amount raised from IPOs in Hong Kong for the first 11 months of 2025 increased by 228.1% year-on-year[1] - A decrease in the year-on-year growth rate for IPO fundraising is expected in 2026 due to a high base effect[1] U.S. Market Overview - The Dow Jones Industrial Average closed at 48,367 points, down 0.2%[2] - The Hang Seng Index futures closed at 25,880 points, indicating a slight premium of 25 points[2] Macro Economic Indicators - The U.S. housing price index rose by 1.7% year-on-year in October, slightly lower than the 1.8% increase in September[3] - The Chicago PMI for December was reported at 43.5, up from 36.3 in November and above the market forecast of 39.5[3] Industry Dynamics - The robotics sector in Hong Kong saw a collective rise, with companies like UBTECH (9880 HK) and Sanhua Intelligent Controls (2050 HK) increasing by 8.3% and 12.5% respectively[4] - In the consumer sector, prices for Labubu series products on second-hand platforms have significantly dropped, impacting Pop Mart (9992 HK), which fell by 4.5%[4] Healthcare Sector Performance - The Hang Seng Healthcare Index decreased by 0.5%[5] - Pharmaceutical manufacturing revenue in China for January to November 2025 fell by 2.0% year-on-year, with total profits down by 1.3%[5] - Retail sales in physical pharmacies dropped from RMB 53.8 billion in September to RMB 52.3 billion in October[5]